Sugi Predict

Sugi Predict / Compounds / SCHEMBL197618

SCHEMBL197618

SCHEMBL197618

O=C(O)[C@@H](O)c1ccccc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.52
▸ MAPK1 P28482 1/20 0.52
▸ FABP4 P15090 1/20 0.51
▸ FABP5 Q01469 1/20 0.51
▸ CASP1 P29466 1/20 0.50
▸ ACP3 P15309 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.45
▸ IGFBP3 P17936 1/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ CXCL8 P10145 1/20 0.44
▸ CYP2D6 P10635 1/20 0.43
▸ GLS O94925 1/20 0.42
▸ AOC3 Q16853 1/20 0.42
▸ ADRB2 P07550 1/20 0.42
▸ ADRB1 P08588 1/20 0.42
▸ CES2 O00748 1/20 0.41
▸ CES1 P23141 1/20 0.41
▸ KDM4C Q9H3R0 1/20 0.41
▸ IDO1 P14902 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28162815 1.00 LMNA (0.52) LMNAMAPK1FABP4FABP5CASP1
SCHEMBL29501895 1.00 LMNA (0.52) LMNAMAPK1FABP4FABP5CASP1
SCHEMBL29398319 1.00 LMNA (0.52) LMNAMAPK1FABP4FABP5CASP1
SCHEMBL28162814 1.00 LMNA (0.52) LMNAMAPK1FABP4FABP5CASP1
SCHEMBL29465008 1.00 LMNA (0.52) LMNAMAPK1FABP4FABP5CASP1
SCHEMBL24733 1.00 LMNA (0.52) LMNAMAPK1FABP4FABP5CASP1
SCHEMBL24732 1.00 LMNA (0.52) LMNAMAPK1FABP4FABP5CASP1
Hydrochloric Acid SCHEMBL1374028 0.98 LMNA (0.50) LMNAMAPK1FABP4FABP5CASP1
SCHEMBL28848826 0.98 LMNA (0.50) LMNAMAPK1FABP4FABP5CASP1
SCHEMBL28180751 0.98 LMNA (0.50) LMNAMAPK1FABP4FABP5CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 339 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3122708-B1 AN IMPROVED PROCESS FOR THE PREPARATION OF EXAMETAZIME JUBILANT GENERICS LTD (IN) 2024-06-12 — — EP claimed
CN-113136572-B Preparation method of chiral molybdate mesostructured film 同济大学 2022-04-08 — — CN claimed
CN-113136572-A Preparation method of chiral molybdate mesostructured film 同济大学 2021-07-20 — — CN claimed
CN-109868293-A A kind of method that enzymatic transesterification kinetics split 2- chloro mandelic acid enantiomer 湖南理工学院 2019-06-11 — — CN claimed
US-10252986-B2 Process for the preparation of exametazime Jubilant Generics Limited (IN) 2019-04-09 — — US claimed
EP-3122708-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF EXAMETAZIME Jubilant Life Sciences Limited (IN) 2017-02-01 — — EP claimed
US-20170015620-A1 PROCESS FOR THE PREPARATION OF EXAMETAZIME JUBILANT DRAXIMAGE INC. (CA) 2017-01-19 — — US claimed
EP-2215040-B1 PROCESS FOR PREPARING (S) 2-(2-CHLOROPHENYL)-2-HYDROXY-ETHYL CARBAMATE SK BIOPHARMACEUTICALS CO LTD (KR) 2016-06-01 — — EP claimed
WO-2015145302-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF EXAMETAZIME JUBILANT LIFE SCIENCES LIMITED (IN) 2015-10-01 — — WO claimed
US-8796488-B2 Process for the preparation of lacosamide EUTICALS S.P.A. (IT) 2014-08-05 — — US claimed
EP-1397335-B1 RESOLUTION PROCESS FOR (R)-(-)-2-HYDROXY-2-(2-CHLOROPHENYL)ACETIC ACID SANOFI AVENTIS (FR) 2010-11-10 — — EP claimed
EP-2215040-A1 IMPROVED PROCESS FOR PREPARING 2-(SUBSTITUTED PHENYL)-2-HYDROXY-ETHYL CARBAMATES Janssen Pharmaceutica, N.V. (BE) 2010-08-11 — — EP claimed
US-20090105498-A1 IMPROVED PROCESS FOR PREPARING 2-(SUBSTITUTED PHENYOL)-2-HYDROXY-ETHYL-CARBAMATES JANSSEN PHARMACEUTICA, N.V. (BE) 2009-04-23 — — US claimed
WO-2009050587-A1 IMPROVED PROCESS FOR PREPARING 2-(SUBSTITUTED PHENYL)-2-HYDROXY-ETHYL CARBAMATES JANSSEN PHARMACEUTICA, N.V. (BE) 2009-04-23 — — WO claimed
US-7381835-B2 Resolution of racemic mixtures using an amine SANOFI-AVENTIS (FR) 2008-06-03 — — US claimed
CN-1276907-C Spliting method of (r)-(-)-2-hydroxyl-2-(2-chlorphenyl)acetic acid SANOFI AVENTIS (FR) 2006-09-27 — — CN claimed
US-20040242921-A1 Resolution process for (r)-(-)-2-hydroxy-2-(2-chlorophenyl) acetic acid SANOFI (FR) 2004-12-02 — — US claimed
CN-1547566-A Spliting method of (r)-(-)-2-hydroxyl-2-(2-chlorphenyl)acetic acid ��ŵ�Ѻϳ�ʵ���� 2004-11-17 — — CN claimed
EP-1397335-A1 RESOLUTION PROCESS FOR (R)-(-)-2-HYDROXY-2-(2-CHLOROPHENYL)ACETIC ACID Sanofi-Aventis (FR) 2004-03-17 — — EP claimed
WO-2003000636-A1 RESOLUTION PROCESS FOR (R)-(-)-2-HYDROXY-2-(2-CHLOROPHENYL) ACETIC ACID SANOFI-SYNTHELABO (FR) 2003-01-03 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242921-A1 Resolution process for (r)-(-)-2-hydroxy-2-(2-chlorophenyl) acetic acid GRHPR, HCAR2, HCAR1 LMNA 3718/4885MAPK1 2557/4885FABP4 2146/4885
US-20090105498-A1 IMPROVED PROCESS FOR PREPARING 2-(SUBSTITUTED PHENYOL)-2-HYDROXY-ETHYL-CARBAMATES EPM2A, PYGB, KDM1B LMNA 371/4885MAPK1 1541/4885FABP4 4813/4885
US-20170015620-A1 PROCESS FOR THE PREPARATION OF EXAMETAZIME CUL5, SAMM50, ADRM1 LMNA 1575/4885MAPK1 4410/4885FABP4 2229/4885
US-10252986-B2 Process for the preparation of exametazime CUL5, SAMM50, ADRM1 LMNA 1575/4885MAPK1 4410/4885FABP4 2229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.